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Most cells in the human body are supported by an intricate network ofmacromolecules 
termed extracellular matrix (ECM)1. An important function of the ECM is to 
provide structural support for cells during development and through adult life in 
homeostasis and disease. Each organ, or functional organ unit, is characterized by 
a unique ECM signature, specific for supporting the functions of the resident cells 
and microenvironment. Next to offering physical support, ECM guides segregation, 
establishment, and maintenance of cell differentiation status2. To achieve these ends, 
ECM can be found as interstitial arrangement of interconnected subunits, or as highly 
specialized frameworks such as the epithelial and endothelial basement membrane2. 
Additionally, ECM acts as a depot for growth factors, receptors, and hormones, and 
regulates tissue hydration and pH. This multi-functionality draws from the complex 
biochemical and biomechanical interactions between proteins, carbohydrates, and 
water, which create unique adhesion surfaces and form physical barriers between 
different cell layers. These interactions result in a tissue-specific composition 
and architecture that perfectly fits the functions of the inhabiting cells3. As the 
microenvironment in an organ changes, so does the ECM. Cell-ECM interactions are 
highly dynamic and usually involve the synthesis and higher order interconnection of 
new ECM macromolecules and enzyme-dependent post-translational modifications. 
Thus, ECM components can provide physical support for cells and simultaneously 
act as active modules in signaling to guide cell growth, migration, function and fate2. 
However, when the homeostasis of an organ is disturbed, aberrant regulation of ECM 
synthesis, remodeling and degradation may have disastrous effects on organ function. 
In this thesis, I set out to uncover yet unknown regulators of ECM-related disorders 
such as fibrosis and cancer. In this chapter I will give a brief introduction of the key 
components and functions of the ECM and illustrate how cells and ECM can interact to 
regulate cell function in health and disease.
KEY MOLECULES IN EXTRACELLULAR MATRIX
The most abundant components of the ECM are collagens; large rod-shaped proteins 
designed to give the ECM its mechanical and structural properties. The human 
genome encodes for 28 types of collagens and their structural hallmark are the triple 
helices that, depending on the combination of α-chains, can form either non-fibrillary 
structures or self-assemble into collagen fibrils1 (Figure 1). The triple helix consists 
of α-chains with the repetitive amino acid sequence Gly-X-Y, where X and Y can be 
any amino acid. The X and Y positions are often occupied by hydroxylated forms of 
lysine and proline, amino acids mainly found in collagens2. Collagens also contain non-
helical regions that can be short (in case of the N- and C-terminal telopeptides in the 
fibril forming collagens) or can cover the larger part of a collagen molecule (seen in 
large stretches of collagen XII)4. The main fibril-forming collagens (type I, II, III, V and XI) 
make up about 80% of the total collagen mass in the human body, and provide tensile 
strength in vessels, bone, tendon, skin, and cartilage4. Non-fibrillary collagens (such as 
collagen type IV, VIII and X) form networks, associate with fibril networks (collagen type 
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IX, XII and XIV), occur as transmembrane molecules (collagen type XIII and XVII), or form 
flexible microfibrils that assemble into filamentous networks (collagen type VI)4. Type 
IV collagen forms chicken-wire-like structures and is one of the main components of 
the epithelial and endothelial basement membrane. Cells are connected to collagens 
through integrin receptors and discoidin domain receptors (DDR), each recognizing 
specific amino acid residues that allow simultaneous binding and signaling2,5. These 
connections between cells and collagens are crucial for cell motility, proliferation, 
cytokine secretion and ECM remodeling2,5. Collagen biosynthesis encompasses a 
series of intra- and extracellular post-translational modifications performed by a 
variety of enzymes, collectively termed the ‘collagenome’. During disease, changes or 
aberrations in collagen biosynthesis may lead to altered levels of collagen production. 
In turn, excessive levels of collagens may result in the alteration or even destruction of 
tissue architecture4.
A second major component of the extracellular space is the family of fibronectins, 
massive glycoproteins that connect the structural components of the ECM to each 
other and to cells6. Many of the ECM components described above interact through 
connections with the multi-domain protein fibronectin. Fibronectins are secreted by 
the cell as large glycoproteins that assemble into fibrillary structures and connect the 
cell to its surrounding ECM via integrin receptors7. Fibril formation is mainly dependent 
on the α5β1 integrin and requires coordinated expression of both molecules. Each 
fibronectin subunit consists of three types of modules termed repeats, each of 
which has a distinct structure: type I, II and III repeats. These subunits are designed 
to specifically aid in fibronectin self-assembly or associate with other ECM proteins 
or receptors, including gelatins, fibrin, heparins, integrins, or membrane-bound 
syndecans6. Fibronectin assembly involves the interactions of a specific pair of type 
III repeats called the Arg-Gly-Asp (RGD) motifs with integrins on the cell membrane. 
Alternative splicing of the fibronectin transcript generates different mRNAs that in 
turn code for specific protein isoforms (e.g. cellular and plasma fibronectin), each with 
distinct functions. Cellular fibronectin is a multimeric insoluble protein that includes 
the type III repeats that form the so called EDA and EDB segments, and are thought to 
play a role in cell adhesion and fibril stability, respectively. Plasma fibronectin lacks the 
EDA and EDB segments and circulates in the bloodstream as dimeric soluble protein. 
What has become clear is that EDA and EDB modules are marginally expressed during 
normal organ homeostasis, but are increased during injury and disease6.
Another group of molecules comprising ECM are the proteoglycans. Proteoglycans 
consist of a core protein that is heavily glycosylated through the covalent binding of 
one or more glycosaminoglycans (GAGs)2 and can be classified into three major groups 
based on the type of GAG side chain. GAGs include heparin sulphate, chondroitin 
sulphate, dermatan sulphate, hyaluronan, and keratan sulphate. One of the primary 
functions of proteoglycans is to regulate the biochemical and hydrodynamic 
characteristics of ECM that can be assigned to their signature GAG repeats, which bind 
water and provide hydration and compression resistance to tissues2. Proteoglycans 




a wide variety of ECM components, such as laminin and fibronectin8. In addition to 
being constituents of ECM, certain proteoglycans are known to be involved in the 
assembly of collagen fibrils, including the small leucine-rich repeat proteoglycans 
decorin and biglycan9. Taken together, the interconnection between different ECM 
modules creates a complex and tailored meshwork for cells to guide their function 
and fate. Additional post-translational modifications such as proteolytic cleavage, 
citrullination, cross-linking, nitrosylation, and glycosylation provide another tier of 
ECM specialization. Cells interact with the ECM through specialized receptors and 
membrane-bound protein complexes including integrins, DDRs, and cell surface 
proteoglycans. In this respect, cells transduce biochemical and biomechanical signals 
Figure 1. Schematic representation of collagen biosynthesis.
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to the ECM and vice versa, in order to maintain tissue homeostasis. A full description 
of ECM and its functions is beyond the scope of this thesis (for excellent review articles 
see1,2,8).
EXTRACELLULAR MATRIX IN HOMEOSTASIS AND DISEASE
All cell types synthesize and deposit ECM macromolecules required for their function, 
thus participating in maintaining tissue homeostasis. In response to tissue injury, the 
human body initiates mechanisms that drive immediate repair and remodeling of the 
injured site. The so-called wound healing response is characterized by three stages: 
inflammation, cell proliferation, and finally the maturation and remodeling of the 
newly synthesized ECM. Initially, these stages were used for the description of dermal 
wounding, but are readily applicable to the healing processes of multiple organ 
systems10, with exception of the central nervous system. The timing and amplitude of 
wound healing are key for proper restoration of tissue morphology and function. 
Chronic organ injury causes a disturbed and prolonged wound healing response, with 
aberrant deposition and remodeling of the newly synthesized ECM components—
termed fibrosis (Figure 2). Organ fibrosis often starts with repeated injury of 
epithelial or endothelial cells, which release pro-inflammatory molecules, including 
cytokines and chemokines such as transforming growth factor (TGF)β1. Mononuclear 
inflammatory cells migrate toward the site of injury where they consume cellular debris, 
remove dead and dying cells, and produce even more cytokines. The secretion of ECM 
degrading enzymes promotes the activation of effector cells—such as pericytes and 
fibroblasts—and the enzymatic release of ECM bound cytokines11. Eventually, more 
effector cells migrate into the wound area and undergo a phenotypic shift toward 
myofibroblasts: cells specialized in ECM production, contraction and remodeling12. 
The balance between proteolytic degradation and synthesis shifts towards excessive 
ECM deposition and together with a disturbed remodeling, result in a haphazard 
accumulation of ECM components. Increased cross-linking of the collagen molecules 
by both enzymatic and non-enzymatic means make the collagen difficult to degrade 
and causes loss of tissue functionality and architecture, and at the same time results 
in stiffening of the ECM. In addition to distorting the normal tissue architecture, 
fibrous ECM alters the behavior and function of the cell types present, by means of 
both biochemical and biomechanical signaling, eventually leading to chronic organ 
dysfunction10,13–15. 
The key cells in fibrotic disorders are the so-called myofibroblasts, characterized by 
a synthetic and contractile phenotype. In the early phases of wound healing, local 
effector cells migrate into the injured site and acquire bundles of microfilaments that 
contain β- and γ-cytoplasmic actins12. Over time, through the action of growth factors 
such as TGFβ1, together with de novo expression of cellular fibronectin, myofibroblasts 
start to express the smooth muscle cell actin isoform smooth muscle alpha actin (SM 








Through specialized integrin focal adhesions, myofibroblasts connect their actin 
cytoskeleton to the surrounding ECM and thereby transduce contractile forces into 
the environment. This results in straining and compaction of ECM molecules, which in 
turn mechanically feedback to enhance the pro-fibrotic phenotype17. Additionally, the 
mechanical properties of the ECM itself are thought to guide load-bearing collagen 
assembly via the interactions with fibronectin.
Another form of fibrous tissue can be found in and around several forms of cancer, 
termed tumor desmoplastic stroma. Desmoplastic tumors are characterized by foci of 
active myofibroblasts together with increased deposition and an altered organization 
of ECM proteins18,19. Unlike organ fibrosis, desmoplastic stromal ECM is thought to be 
synthesized by cancer associated fibroblasts (CAFs), as a result of the dysregulated 
cytokine expression by cancer cells20. Recent findings indicate that the desmoplastic 
stroma is not just an integral part of the tumor but progressively contributes to tumor 
cell oncogenicity and dissemination21–24. ECM in the tumor stroma is thought to 
influence both the biochemical and biomechanical signaling. Not only is ECM-related 
mechanosignaling thought to promote the aggressiveness of existent tumor cells, but 
also promote the transformation of normal epithelial cells into myofibroblast-like cells 
that support tumor growth, compromise drug delivery, and impair the infiltration of 
anti-tumor inflammatory cells25,26. 
Despite decades of research, both fibrosis and fibrotic tumors have abysmal options 
for treatment27–29. In the past, the main focus in the development of therapies for these 
pathologies lay in manipulating biochemical signaling cascades without taking the 
role of the ECM and the extracellular environment into account. The notion that ECM 
is of paramount importance in the pathophysiology and thus in the development of 
effective therapies, has spawned an entire field of research dedicated to ECM-related 
disorders. Understanding the molecular processes that underlie the pathological 
accumulation of ECM and consequential signaling through the ECM in both fibrosis 
and cancer will aid in the development of anti-fibrotic and anti-cancer therapies.
ECM AS SIGNAL TRANSDUCER IN FIBROSIS
Biochemical signaling
Cells react to signals from the environment using different mechanisms, including 
biochemical and biomechanical cues. The studies on biochemical signaling have their 
roots in endocrinology studies of the 1970’s, when Martin Rodbell first described the 
actions of the hormone glucagon on guanosine triphosphate (GTP) binding proteins—
so called G-proteins—and their associated G-protein coupled receptors30. Since then 
several tens of signal transduction pathways have been uncovered and depending 
on the cell type, may affect metabolism, cell division, growth, shape and motility. 
Biochemical signal transduction begins when an extracellular signaling molecule, 
known as ligand, binds to a membrane bound receptor. One group of ligands for such 
receptors is the ECM itself. Moreover, ECM often acts as a depot for signaling ligands 
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1including hormones, cytokines, growth factors, signaling ions, and free radicals. The controlled release of these agents allows for a strictly controlled regulation of receptor 
activation and subsequent signal transduction. Many growth factors are synthesized 
as an inactive precursor form, transported to the extracellular space and subsequently 
stored in the ECM. When released by either mechanical or proteolytic means, they can 
activate cell surface receptors and initiate an intracellular signaling cascade. 
The pro-fibrotic TGFβ1 is an example of a growth factor that is kept inactive in the 
ECM through its association with the latency associated protein (LAP) and latent TGF- 
binding proteins (LTBPs), together forming the large latency complex (LLC)31–34. The 
LLC is capable of binding to several ECM components such as fibrillins and vitronectin, 
providing a growth factor reservoir. Latent TGFβ1 is freed from the ECM via several 
mechanisms: proteolytic cleavage by metalloproteinases (MMPs) and glycosidases, or 
mechanical liberation through association with integrins. The RGD motif in the LAP 
is being recognized by the integrins αvβ5, αvβ3, and β132. Upon mechanical strain, 
the conformation of the complex changes, thereby releasing the TGFβ1 dimer34,35. 
Myriad studies have implicated the actions of TGFβ1 in the processes of wound 
healing, fibrosis and cancer, but although the basic cascade is similar in all, cell-type 
specific expression patterns together with inter-pathway cross-talk result in drastically 
different outcomes36,37. For instance, TGFβ1 has been shown to be anti-proliferative 
in epithelial cells38, whereas it increases the proliferative capacity of fibroblasts39,40. 
Moreover, studies in cancer suggest that TGFβ1 can act anti-proliferative in the early 
stages of tumor growth. However, deregulated TGFβ1 signaling has also been shown 
to boost cancer cell proliferation directly, or via alteration of the microenvironment41. 
Inside the cell, growth factor receptors transduce the signal toward the nucleus. Often, 
multiple membrane-bound and cytosolic proteins aggregate at the receptor(s) to 
form signaling complexes42. Activated receptor complexes induce post-translational 
modifications on cytosolic signaling proteins, of which phosphorylation by kinases 
is the most well-known. Some growth factor signaling cascades activate signaling 
molecules that directly translocate to the nucleus where they bind to DNA and act 
as transcription factors and modulate gene transcription. Other signaling cascades 
have multiple intermediate signaling proteins that act as transduction relay for the 
signal to travel into the nucleus. In the case of TGFβ1, interaction with its membrane-
bound receptors initiates a signaling cascade that activates the signal-propagating 
complex of Smad transcription factors. Phosphorylated Smad2 and Smad3 complex 
with Smad4 and translocate to the nucleus, where they associate with DNA-binding 
proteins or the DNA itself, respectively37. Smad3 and Smad4 contain an evolutionary 
conserved Mad homology (MH1) domain that recognizes an 8-bp palindromic DNA 
sequence, GTCTAGAC. Signal propagation of Smads depend on the accessibility of 
chromatin and availability of co-activators, co-repressors, and master transcription 




Throughout mammalian life, an organism is constantly being subjected to mechanical 
forces such as pressure force resulting from earth’s gravity. Apart from external forces, 
the body experiences multiple internal mechanical stimuli, including hydrostatic and 
cellular compression, fluid shear stress, tensional force, and cell traction force, all having 
profound effects on cells and the ECM. For instance, during human development, the 
cells of the inner cell mass are being pushed outwards by the excreted liquid in the 
blastocoel cavity. These mechanical cues cause transcription factors such as Sox2 and 
Oct4 to be upregulated to maintain pluripotency, which suggest that the embryonic 
transcriptional program can be influenced by mechanical forces44. Moreover, epithelial 
and endothelial cell layers exhibit pronounced apical-basolateral polarity due to the 
mechanical signaling of fluid shear stress and constriction on the apical side together 
with integrin-mediated traction and compression from the basement membrane at the 
basolateral side. Other mechanical rheostats put a halt on the cell division machinery 
to make sure organs stop expanding at the right moment in development45,46.
 
Cells are able to sense and respond to their mechanical environment through specialized 
structures called focal adhesions. The term sensing is used metaphorically and refers 
to extracellular features that can measurably alter a cell’s dynamics, function, shape or 
fate47. Focal adhesions are cell-matrix adhesion sites that function as relays between 
the ECM and the intracellular cytoskeleton. More specifically, focal adhesions are the 
subcellular structures that regulate the mechanical connection and signaling from and 
to the ECM, and at the same time function as a biochemical hub for the assembly of 
multiple signaling proteins at sites of integrin binding and clustering. Lacking kinase 
activity, integrins mainly act as scaffolding proteins for the recruitment of a wide variety 
of signaling modules. To discriminate between different ECM components, integrins 
have the ability to associate as different heterodimers containing an α and β subunit. 
Mammals express 18 α subunits and 8 different β subunits, which can dimerize and 
form 24 different integrin receptors48. When integrin subunits engage their ligand, 
talin and kindlin proteins binds to the β-integrin subunit cytoplasmic tail and initiate a 
conformational change that in turn enhances the affinity for its ligand49. These short-
lived adhesions, often termed ‘nacent adhesions’ only last for about 60 seconds, unless 
they mature into focal complexes. In the latter case, the binding of talin and kindlin 
triggers the sequestering of multiple scaffolding and signal transduction proteins 
including filamin, paxillin, vinculin, α-actinin, integrin-linked kinase (ILK), and focal 
adhesion kinase (FAK)49. Together, the aggregated proteins link the integrins with the 
actin cytoskeleton, and allow bidirectional transduction of mechanical forces. 
Actin stress fibers can be typically divided into three groups—dorsal stress fibers, 
transverse arcs, and ventral stress fibers—that all have a specific function and 
intracellular localization50. Dorsal stress fibers are long, non-contracting bundles of 
actin that are cross-linked by α-actinin and span the dorsal side of a cell. Transverse 
arcs are described as long, curved actin bundles with alternating α-actinin and myosin 
bands, and are not connected to any focal adhesions, but move centripetally along 
the dorsal stress fibers toward the center of a cell. Finally, ventral stress fibers have 
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1the characteristics of both dorsal stress fibers and transverse arcs. They span the cell as thin linear bundles where they are connected to focal adhesions, but toward the 
center they contain repetitive stretches of α-actinin and non-muscle myosin II that 
allows bidirectional contraction. When bipolar myosin motors move along the actin 
fibers, α-actinin interlocks adjacent actin fibers together to maintain tension51. The 
increased tension between the ECM and the actomyosin cytoskeleton—commonly in 
the form of ventral stress fibers—initiates clustering of integrins to form the larger focal 
adhesions52. Additionally, it is thought that increased actomyosin-generated forces 
result in a cascade of protein unfolding events. Such conformational changes could 
expose otherwise obscured binding sites, consequently modulating the recruitment 
of additional proteins to the adhesion47.
Transmission of mechanical cues via integrin receptors sets in motion a cascade of 
conformational changes that allow a multitude of signaling proteins to aggregate 
at focal adhesions. Many of these proteins function as signal transducer and 
possess kinase activity to phosphorylate their substrates, often proteins that also 
fulfill functions in biochemical signaling cascades. Mechanical signals can alter the 
concentration of second messengers such as Ca2+, inositol triphosphate, cyclic AMP and 
nitric oxide, or activate signaling proteins, such as MAP kinases and Rho-family small 
GTPases44. The activation of such signaling cascades lead to changes in the activity of 
transcriptional modulators, and as such, regulate the transcription of multiple genes. 
Another example of how mechanical cues modulate transcriptional programs is the 
activation of the transcriptional co-activators YAP and TAZ, the output of the Hippo 
signaling cascade. Both YAP and TAZ are actively sequestered in the cytoplasm when 
the Hippo pathway is active, by means of phosphorylation by the core kinase complex, 
and association with 14-3-3 proteins at cellular junctions. When the core kinase 
complex—consisting of LATS1/2, MST1/2, SAV and MOB—is inactivated, YAP and TAZ 
cannot be phosphorylated. Upon dephosphorylation, YAP and TAZ translocate to the 
nucleus where they associate with transcription factors, including TEAD’s, to modulate 
transcription of target genes. Besides being subjective to biochemical modulation, YAP 
and TAZ have been shown to be mechanosensitive45. Although the exact mechanism 
remains elusive, it is thought that actin polymerization is the key factor for YAP and TAZ 
nuclear translocation53. 
Transduction of mechanical signals often utilizes the same intracellular protein 
complexes as biochemical signaling cascades. As such, biomechanical and biochemical 
signaling converge in the activation of transcriptional modulators such as transcription 
factors, chromatin remodeling enzymes and a multitude of co-activators and co-
repressors43. Recently, several studies indicated that YAP and TAZ share signaling 
characteristics with the TGFβ signaling pathway54–57. Understanding these interactions 
and how they modulate the myofibroblast phenotype is crucial for the development 
of therapies that target the accumulation of ECM in fibrosis. 
20
CHAPTER 1
OUTLINE OF THIS THESIS
Despite decades of intensive research, attempts in developing effective therapeutics 
against ECM-related disorders, including fibrosis, have largely failed25,27,29. The 
disappointing results from clinical trials targeting the myofibroblast or the fibrotic 
tissue itself suggest that the nature of the stromal response is far more complex 
than expected. An explanation for this discrepancy is the lack of understanding of 
biomechanical signaling and the communication with biochemical signaling cascades. 
This demands for thorough investigation of the myofibroblast phenotype and the 
pathophysiology of fibrotic disorders. The overall aim of this work is to uncover yet 
unknown biochemical and biomechanical signals that regulate the myofibroblast 
phenotype in fibrosis and to open up new avenues for development of anti-
fibrotic therapies. 
This thesis focuses on several aspects of biochemical and biomechanical activation of 
myofibroblasts in the context of tissue fibrosis. As discussed above, YAP has recently 
been discovered to function as mechanical rheostat in mesenchymal stem cells. In 
Chapter 2 we sought to delineate the functions of YAP in dermal fibroblasts and in the 
pathology of a fibroproliferative disorder of the palmar fascia: Dupuytren disease. We 
investigated whether YAP deficient fibroblasts are still able to phenotypically switch 
to myofibroblasts upon stimulation with the pro-fibrotic cytokine TGFβ1. Additionally, 
we investigated the expression and localization profile of YAP in Dupuytren disease 
biopsies. 
The past decade saw a shift in how scientists view biochemical signaling cascades. 
Instead of regarding them as isolated entities, they were found to interconnect 
and form complex networks that govern a variety of cellular functions. Chapter 3 
summarizes the current knowledge on how the TGFβ, WNT and YAP/TAZ signaling 
cascades interact on multiple levels of cellular homeostasis, and how these interactions 
may drive the initiation and progression of fibrosis.
Chapter 4 forwards on the interaction between TGFβ/Smad signaling and YAP, 
and shows how YAP regulates the myofibroblast phenotype both on protein and 
gene level. Furthermore, we show how the actin cytoskeleton regulates the nuclear 
accumulation of YAP on TGFβ1 exposure, and how this is partly dependent on YAP/
Smad interactions. Moreover, we describe how the benzoprophyrin derivative 
verteporfin inhibits both YAP and Smad2/3 nuclear accumulation, and the expression 
of signature myofibroblast genes, opening up new avenues for anti-fibrotic therapies. 
Spectrins are specialized scaffolding proteins that play a crucial role in maintaining 
plasma membrane integrity, and have been found to provide mechanical stability to 
cells. In Chapter 5 we focus on the role of spectrin proteins in mechanosensing and 
the myofibroblast phenotypical switch of fibroblasts.
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1L-ascorbic acid, commonly referred to as vitamin C, acts a co-factor in eight different types of enzymatic reactions, three of which are crucial in the biosynthesis of collagen. 
Chapter 6 describes how vitamin C regulates the biosynthesis of collagens and how 
this is linked to TGFβ1 exposure and the myofibroblast phenotype. 
In Chapter 7 we discuss how the abovementioned biochemical and biomechanical 
cues—YAP, spectrins, and vitamin C—may affect the development of ECM related 
disorders. Finally, we conclude with a discussion of the clinical and therapeutic 
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